FDA Accepts Trastuzumab Biosimilar for Review

Article

Trastuzumab (Herceptin) is indicated to treat HER2+ breast and gastric cancers.

Today, Samsung Bioepis announced that the FDA accepted for review a biologics license application for SB3, a biosimilar of trastuzumab (Herceptin), according to a press release.

This drug is the first oncology biosimilar submitted to the FDA for approval.

Samsung Bioepis said that if approved, SB3 would be commercialized by Merck.

About trastuzumab (Herceptin)

Trastuzumab is a Genentech oncology biologic drug that is indicated for multiple types of cancer.

Currently, trastuzumab is approved for early stage HER2+ breast cancer that has or has not spread to the lymph nodes. It is also approved to treat patients with metastatic HER2+ breast cancer.

Trastuzumab is approved as a combination therapy for treatment-naïve patients with HER2+ metastatic stomach or gastroesophageal junction cancer.

The most common side effects associated with trastuzumab are fever, nausea, vomiting, infusion reactions, diarrhea, infections, cough, headache, feeling tired, shortness of breath, rash, low white and red blood cell counts, and muscle pain, according to Genentech.

Related Videos
Team of care workers with women at the center -- Image credit: Delmaine Donson/peopleimages.com | stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.